A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma. The phase Ib part of this study is to determine the recommended phase 2 dose (RP2D) of C-CAR088 in the targeted patient population.

Trial Details

NCT ID
NCT05521802
Phase
PHASE1 / PHASE2
Sponsor
Shanghai AbelZeta Ltd.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • ≥ 18 years of age, male or female patients
  • Relapsed or refractory multiple myeloma
  • Have been treated with ≥ 3 prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory drug, and had progressed du…
  • Had measurable disease as defined by any of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →